David Malcom Rodman - 11 Sep 2024 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Medical Officer
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
11 Sep 2024
Net transactions value
+$9,567
Form type
4
Filing time
12 Sep 2024, 16:32:12 UTC
Previous filing
13 Aug 2024
Next filing
15 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Options Exercise $2,710 +5,018 +4.4% $0.5400 119,256 11 Sep 2024 Direct
transaction MLYS Common Stock Options Exercise $6,857 +6,349 +5.3% $1.08 125,605 12 Sep 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Options Exercise $0 -5,018 -20% $0.000000 20,069 11 Sep 2024 Common Stock 5,018 $0.5400 Direct F1, F2
transaction MLYS Stock Option Options Exercise $0 -6,349 -3.6% $0.000000 170,786 12 Sep 2024 Common Stock 6,349 $1.08 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F2 The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
F3 Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F4 The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.